Individuals with severe medical conditions: Kidney, liver, or heart disease may complicate metabolism and safety
Note: increlex (mecasermin) is FDA-approved recombinant native IGF-1 for severe primary IGF-1 deficiency distinct molecule from LR3
Inflammatory bowel disease (IBD) patients exhibit altered gut microbial diversity, such as an imbalance between Firmicutes and Bacteroidetes , an increase in Proteobacteria , and the depletion of Roseburia species [31, 32]
This approach allows patients to monitor their initial response to the medication, particularly any gastrointestinal side effects such as nausea or diarrhoea, without the added stress of work obligations or important social events
And the most significant results usually occur after 3 to 6 months of consistent use, as the dose gradually increases